TY - JOUR
T1 - Exploration of small-molecule entry disruptors for chikungunya virus by targeting matrix remodelling associated protein
AU - Kumar, Avinash
AU - Rathi, Ekta
AU - Kini, Suvarna Ganesh
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Background and purpose: A genome-wide clustered regularly interspaced short palindromic repeatsassociated protein 9-based screen has revealed that the cell adhesion molecule matrix remodelling associated protein 8 (Mxra8) acts as an entry mediator for many alphaviruses including chikungunya virus. The first Xray crystal structure reported for Mxra8 a few months ago has a low-resolution of 3.49Å. Experimental approach: Homology modelling of Mxra8 protein was done employing the SWISS-MODEL and PRIME module of Maestro. To design novel Mxra8 inhibitors pharmacophore guided fragment-based drug design and structure-based virtual screening of Food and Drug Administration approved drug libraries were undertaken. Molecular docking and molecular dynamics (MD) simulations study were carried out to validate the findings. Findings / Results: The molecule H1a (dock score: -6.137, binding energy: -48.95 kcal/mol, and PHASE screen score: 1.528816) was identified as the best hit among the fragment-based designed ligands. Structurebased virtual screening suggested histamine, epinephrine, and capreomycin as potential hits which could be repurposed as Mxra8 inhibitor. MD simulations study suggested that only small molecules like histamine could be a potential inhibitor of Mxra8. H-bond interaction with Arg58 and Glu200 amino acid residues seems to be crucial for effective binding. Conclusion and implications: To the best of our knowledge, this is the first report on the design of novel inhibitors against Mxra8 protein to tackle the menace of alphaviruses infections. This design strategy could be used for structure-based drug design against other apo-proteins. This study also advances the application of in silico tools in the field of drug repurposing.
AB - Background and purpose: A genome-wide clustered regularly interspaced short palindromic repeatsassociated protein 9-based screen has revealed that the cell adhesion molecule matrix remodelling associated protein 8 (Mxra8) acts as an entry mediator for many alphaviruses including chikungunya virus. The first Xray crystal structure reported for Mxra8 a few months ago has a low-resolution of 3.49Å. Experimental approach: Homology modelling of Mxra8 protein was done employing the SWISS-MODEL and PRIME module of Maestro. To design novel Mxra8 inhibitors pharmacophore guided fragment-based drug design and structure-based virtual screening of Food and Drug Administration approved drug libraries were undertaken. Molecular docking and molecular dynamics (MD) simulations study were carried out to validate the findings. Findings / Results: The molecule H1a (dock score: -6.137, binding energy: -48.95 kcal/mol, and PHASE screen score: 1.528816) was identified as the best hit among the fragment-based designed ligands. Structurebased virtual screening suggested histamine, epinephrine, and capreomycin as potential hits which could be repurposed as Mxra8 inhibitor. MD simulations study suggested that only small molecules like histamine could be a potential inhibitor of Mxra8. H-bond interaction with Arg58 and Glu200 amino acid residues seems to be crucial for effective binding. Conclusion and implications: To the best of our knowledge, this is the first report on the design of novel inhibitors against Mxra8 protein to tackle the menace of alphaviruses infections. This design strategy could be used for structure-based drug design against other apo-proteins. This study also advances the application of in silico tools in the field of drug repurposing.
UR - http://www.scopus.com/inward/record.url?scp=85092342854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092342854&partnerID=8YFLogxK
U2 - 10.4103/1735-5362.288437
DO - 10.4103/1735-5362.288437
M3 - Article
AN - SCOPUS:85092342854
SN - 1735-5362
VL - 15
SP - 300
EP - 311
JO - Research in Pharmaceutical Sciences
JF - Research in Pharmaceutical Sciences
IS - 3
ER -